Metastatic Triple Negative Breast Cancer: Research & Clinical Trials
Research in mTNBC is focused on understanding tumor biology and developing novel therapies. Clinical trials are exploring immunotherapies, targeted therapies, and combination regimens to improve patient outcomes. Immune checkpoint inhibitors targeting PD-1/PD-L1 pathways have shown encouraging results, particularly in combination with chemotherapy or other targeted agents.
PARP inhibitors continue to be a major area of research, especially in patients with BRCA1/2 mutations. Ongoing trials are evaluating their efficacy both as monotherapy and in combination with immunotherapy. Other targeted therapies under investigation include AKT inhibitors, androgen receptor antagonists, and anti-angiogenic agents, all aiming to disrupt tumor growth pathways.
Novel therapeutic strategies are also focusing on antibody-drug conjugates (ADCs), which allow selective delivery of cytotoxic drugs to tumor cells, minimizing systemic toxicity. Research into biomarkers and genetic profiling is advancing personalized medicine approaches, helping clinicians identify patients most likely to benefit from specific treatments.
Emerging technologies, such as next-generation sequencing (NGS) and CRISPR-based models, are enhancing our understanding of tumor evolution and resistance mechanisms. With over hundreds of ongoing clinical trials globally, the mTNBC research landscape promises new therapeutic avenues and better survival outcomes for patients.